Grace Therapeutics, Inc. Amortization of Intangible Assets
Grace Therapeutics, Inc. (GRCE) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2022-06-21
- Grace Therapeutics, Inc. amortization of intangible assets for the quarter ending 2022-03-31 was $0.00.
- Grace Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-12-31 was $0.00.
- Grace Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Grace Therapeutics, Inc. amortization of intangible assets for fiscal 2021 was $781.00K, a 59.11% decline from fiscal 2020.
- Grace Therapeutics, Inc. amortization of intangible assets for fiscal 2020 was $1.91M, a 2.00% decline from fiscal 2019.
- Grace Therapeutics, Inc. amortization of intangible assets for fiscal 2019 was $1.95M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $0.00 derived: sum of 2 quarters · filed 2022-06-21 | $0.00 derived: sum of 3 quarters · filed 2022-06-21 | $0.00 10-K · filed 2022-06-21 |
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 4 quarters · filed 2022-06-21 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 3 quarters · filed 2022-06-21 | $0.00 derived: sum of 4 quarters · filed 2022-06-21 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 2 quarters · filed 2022-06-21 | $0.00 derived: sum of 3 quarters · filed 2022-06-21 | $319.00K derived: sum of 4 quarters · filed 2022-06-21 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $0.00 derived: sum of 2 quarters · filed 2022-06-21 | $319.00K derived: sum of 3 quarters · filed 2022-06-21 | $781.00K 10-K · filed 2022-06-21 |
| 2020-12-31 | $0.00 10-Q · filed 2022-02-14 | $319.00K derived: sum of 2 quarters · filed 2022-02-14 | $781.00K 10-Q · filed 2022-02-14 | $2.69M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $319.00K 10-Q · filed 2021-11-10 | $781.00K 10-Q · filed 2021-11-10 | $2.69M derived: sum of 3 quarters · filed 2021-11-10 | $3.18M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $462.00K 10-Q · filed 2021-08-12 | $2.37M derived: sum of 2 quarters · filed 2021-08-12 | $2.86M derived: sum of 3 quarters · filed 2021-08-12 | $3.34M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.91M 10-K · filed 2020-06-29 | $2.40M derived: sum of 2 quarters · filed 2021-02-09 | $2.88M derived: sum of 3 quarters · filed 2021-02-09 | $1.91M 10-K · filed 2021-06-22 |
| 2019-12-31 | $485.00K 10-Q · filed 2021-02-09 | $967.00K derived: sum of 2 quarters · filed 2021-02-09 | $1.45M 10-Q · filed 2021-02-09 | $3.40M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-09-30 | $482.00K 10-Q · filed 2020-11-16 | $963.00K 10-Q · filed 2020-11-16 | $2.91M derived: sum of 3 quarters · filed 2020-11-16 | |
| 2019-06-30 | $481.00K 10-Q · filed 2020-08-13 | $2.43M derived: sum of 2 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $1.95M 10-K · filed 2020-06-29 | $1.95M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |